{"id":14463,"date":"2026-02-20T20:35:07","date_gmt":"2026-02-20T20:35:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/14463\/"},"modified":"2026-02-20T20:35:07","modified_gmt":"2026-02-20T20:35:07","slug":"roches-fenebrutinib-shows-promising-results-in-late-stage-trial-for-multiple-sclerosis-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/14463\/","title":{"rendered":"Roche&#8217;s Fenebrutinib Shows Promising Results in Late-Stage Trial for Multiple Sclerosis, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/128093794.cms.jpeg\" captionrendered=\"1\" alt=\"\"\/>Berlin: Swiss pharmaceutical company Roche \u200dsaid on Saturday its experimental multiple sclerosis drug fenebrutinib \u2060met the main goal in a late-stage trial in patients with <a id=\"32929474\" type=\"Denny\" weightage=\"20\" keywordseo=\"primary-progressive-multiple-sclerosis\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/primary+progressive+multiple+sclerosis\" rel=\"nofollow noopener\" target=\"_blank\">primary progressive multiple sclerosis<\/a>, \u200ca rare \u200cform of the disease with few treatment options.<\/p>\n<p>In \u200cthe Phase III study, fenebrutinib cut the risk of worsening disability by 12% compared with Roche&#8217;s Ocrevus, the only approved therapy \u200bfor PPMS, the Swiss \u200bdrugmaker said.<\/p>\n<p>Separation of the treatment curves \u200cwas \u200dseen after 24 weeks, and additional \u200danalyses suggested potential benefits in upper-limb function.<\/p>\n<p>PPMS \u200cis the least common form of multiple sclerosis and is marked by a steady progression of disability from the outset.<\/p>\n<p>Roche said fenebrutinib was the first experimental therapy in more \u200dthan a decade to show a reduction in <a id=\"32929475\" type=\"Denny\" weightage=\"20\" keywordseo=\"disability-progression\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/disability+progression\" rel=\"nofollow noopener\" target=\"_blank\">disability progression<\/a> \u200din a \u2060PPMS study.<\/p>\n<p>The \u2060company said it plans to submit the drug for regulatory approval once additional Phase III data from a relapsing MS trial are available, which it expects in the first half of 2026. <\/p>\n<p>(Reporting by Patricia Weiss, writing by Maria Martinez, editing by Louise Heavens)\n                                                                    <\/p>\n<p>                                    Published On Feb 9, 2026 at 08:05 AM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/1771619707_120_pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Berlin: Swiss pharmaceutical company Roche \u200dsaid on Saturday its experimental multiple sclerosis drug fenebrutinib \u2060met the main goal&hellip;\n","protected":false},"author":2,"featured_media":14464,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[7875,10445,10447,10446,134,10444],"class_list":{"0":"post-14463","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-disability-progression","9":"tag-multiple-sclerosis-treatment","10":"tag-phase-iii-clinical-trial","11":"tag-primary-progressive-multiple-sclerosis","12":"tag-roche","13":"tag-roche-fenebrutinib"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=14463"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/14464"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=14463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=14463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=14463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}